Immunovant, Inc. - 8-K Filing

Immunovant reports Q2 2026 net loss of $97.2 million and positive IMVT-1402 efficacy data in rheumatoid arthritis trial. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 9, 2026, 12:09 UTC

Tickers: $IMVT

Read the full article at SEC EDGAR

Part of the story STARWOOD PROPERTY TRUST, INC. - 8-K Filing (8 articles)

More Regulatory news

Solana Co - 10-Q Filing SEC EDGAR · November 12, 2026, 13:42 UTC
Solana Co - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
DeFi Development Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
Stablecoin Development Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:40 UTC
BCP Investment Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:36 UTC
OneWater Marine Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Moleculin Biotech, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Investcorp Credit Management BDC, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Presurance Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:35 UTC
Corteva, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:34 UTC